CClinicalTrials.gg
CompletedNCT01015001Updated Aug 12, 2010

A Pilot Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation for Patients With Refractory Schizophrenia Treated With Clozapine

A Phase 3 interventional study of Active rTMS x sham (placebo) rTMS and sham rTMS in Schizophrenia and Auditory Hallucinations, sponsored by Hospital de Clinicas de Porto Alegre. Completed at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-08-12.

Sponsored by Hospital de Clinicas de Porto Alegre · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The primary outcome of this study is to evaluate the effects of low frequency subthreshold repetitive Transcranial Magnetic Stimulation applied to the left temporoparietal cortex of patients with refractory schizophrenia on the severity of auditory hallucinations.

The secondary outcome is to evaluate the effects of the same rTMS protocol on quality of life, functionality and general psychopathology.

Read the detailed description

Seventeen patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. First group received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).

Second group received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and refering auditory hallucinations occuring at least 5 times a day.

02

Conditions studied

  • Schizophrenia
  • Auditory Hallucinations

Keywords

  • refractory schizophrenia
  • rTMS
  • auditory hallucinations
03

In context

Hallucinations

132 studies on the registry are indexed under Hallucinations; 36 are open to participants now.

This study's enrollment of 20 is below the median of 50 across 112 interventional studies indexed under Hallucinations.

Browse Hallucinations studies →

Lead sponsor

Hospital de Clinicas de Porto Alegre is the lead sponsor of 450 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with DSM IV TR diagnose of schizophrenia with treatment-resistant auditory hallucinations.
  • Use of at least 400mg/day of clozapine
  • Men and women from 18 to 65 years old
  • Fertile women must be using adequate contraceptive method
  • BPRS score of at least 27

Exclusion criteria

Exclusion Criteria:

  • Suicide risk
  • Patients with epilepsy, brain surgery and/or head trauma in the past, use of cardiac pace maker or metalic clip in the head
  • Diagnose of substance abuse/dependance
  • Severe uncontrolled organic disease that may interfere in the patient´s participation in the study
  • Any other reason that, in the investigator´s opinion, might interfere with the patient´s participation in the study, such as non compliance.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Active rTMS

    1Hz rTMS sessions applied to the left temporoparietal cortex of the subjects

    Procedure: Active rTMS x sham (placebo) rTMS · Procedure: (1Hz) rTMS applied over the left temporoparietal cortex

  • Placebo comparator
    Sham rtms

    Same number of pulses but applied with and angled coil (90 degrees) and placed over the fronto´temporal region

    Procedure: Active rTMS x sham (placebo) rTMS · Procedure: sham rTMS

Interventions

  • ProcedureActive rTMS x sham (placebo) rTMS

    Seventeen right-handed patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. One arm received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC). The other arm received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and referred auditory hallucinations.

    Also known as: EMTr

  • Proceduresham rTMS

    same coil, same number of pulses but using an angled coil(90degres) over the frontotemporal region

    Also known as: Sham

  • Procedure(1Hz) rTMS applied over the left temporoparietal cortex

    20 sessions lasting 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).

06

What researchers measure

Primary outcomes

  1. Evaluate the effects of low frequency repetitive Transcranial Magnetic Stimulation applied over the left temporoparietal cortex of refractory schizophrenic patients on the severity of auditory hallucinations.

    Time frame: 2 years

Secondary outcomes

  1. The secondary outcomes are to evaluate the effects of the same rTMS protocol on their quality of life, functionality and general psychopathology.

    Time frame: 2 years

07

Study locations

1 site
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul, Brazil
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 12, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01015001
Lead sponsor
Hospital de Clinicas de Porto Alegre
First posted
Nov 17, 2009
Start date
May 2008
Primary completion
Dec 2009
Completion
Dec 2009
Last update
Aug 12, 2010

Study contacts

Danilo Jesus, Psychiatrist
principal investigator · Hospital de Clinicas de Porto Alegre
Paulo B Abreu, phd
study director · HCPorto Alegre

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion